Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. View here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGenus Regulatory News (GNS)

Share Price Information for Genus (GNS)

Share Price is delayed by 15 minutes
Get Live Data
2,158.00    26.00 (1.22%)
Bid:
2,156.00
Ask:
2,166.00
Spread: 10.00 (0.464%)
Market Cap: £1.43b
GNS Live PriceLast checked at - London Stock Exchange

Intraday Genus Share Chart

Pre-Close Trading Update

9 Jul 2009 07:00

RNS Number : 3707V
Genus PLC
09 July 2009
 



For immediate release 9 July 2009

GENUS plc

("Genus" or "the Company")

Pre-Close Trading Update

Genus, a world leading animal genetics company, today provides the following update on trading for the six months to 30th June 2009.

Despite tough short-term market conditions driven by the general economic slowdown, Genus continues to expect to report a strong increase in profits for the year to 30 June 2009, with the results benefiting from the international diversity of the Group's operations and the weakness of sterling.

Whilst market conditions for Genus' customers have remained challenging, trading for Genus has been broadly in-line with the Board's expectations during the final quarter. The one exception was a further weakness in the North American dairy market caused by exceptionally low milk prices. Nevertheless, Genus continues to expect that adjusted profit before tax* for the full year will be in line with market expectations. 

For further information contact:-

Genus plc Tel: 01256 345970

Richard Wood, Chief Executive

John Worby, Finance Director

Buchanan Communications Tel: 0207 466 5000

Charles Ryland/Isabel Podda/Jennie Spivey

This announcement is available on the Genus website, www.genusplc.com

*Adjusted Profit Before Tax represents profits before tax excluding non cash items relating to the fair value movement on biological assets, amortisation of acquired intangibles, share based payments and exceptional items. This measure is used to demonstrate underlying performance and in the current year is being amended to exclude only that part of amortisation relating to acquired intangibles. This amendment in accounting treatment amounts to a net reduction in adjusted profit before tax of £0.6m (2008:£0.1m). 

About Genus

Genus creates advances to animal breeding through biotechnology and sells added value products for livestock farming and food producers. Its non-Genetically Modified Organism (GMO) technology is applicable across all livestock species but is only commercialised by Genus in the bovine and porcine farming sectors.

Genus' worldwide sales are made in seventy countries under the trademarks "ABS" (dairy and beef cattle) and "PIC" (pigs) and comprise semen and breeding animals with superior genetics to those animals currently in production. Customers' animals produce offspring with greater production efficiency, milk and meat output and quality and use these to supply the global dairy and meat supply chain. 

The Group's competitive edge has been created from the ownership and control of proprietary lines of breeding animals, the biotechnology used to improve them and the Group's global production and distribution network.

Headquartered in BasingstokeEngland, Genus companies operate in 30 countries on six continents, with research laboratories located in MadisonUSA.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTEAKXPESSNEFE
Date   Source Headline
1st Apr 20085:33 pmRNSDirector/PDMR Shareholding
31st Mar 20084:00 pmRNSTotal Voting Rights
31st Mar 20084:00 pmRNSBlocklisting Interim Review
20th Mar 20082:08 pmRNSHolding(s) in Company
17th Mar 20083:21 pmRNSHolding(s) in Company
13th Mar 20082:00 pmRNSHolding(s) in Company
29th Feb 20082:00 pmRNSTotal Voting Rights
27th Feb 20085:02 pmRNSDirector/PDMR Shareholding
26th Feb 20084:54 pmRNSDirector/PDMR Shareholding
26th Feb 20087:00 amRNSInterim Results
22nd Feb 200811:56 amRNSHolding(s) in Company
31st Jan 20082:00 pmRNSBlocklisting Interim Review
17th Jan 20087:00 amRNSBoard Changes
15th Jan 20088:00 amRNS1st dealings on AIM
15th Jan 20088:00 amRNSDisposal
14th Jan 20085:40 pmRNSHolding(s) in Company
9th Jan 200811:00 amRNSAppointment of New Adviser
2nd Jan 20083:15 pmRNSTotal Voting Rights
30th Nov 20078:00 amRNSTotal Voting Rights
27th Nov 20077:01 amRNSDisposal
15th Nov 20073:39 pmRNSResult of AGM
15th Nov 20077:01 amRNSAGM Statement
12th Nov 20078:24 amRNSAdmission to Official List
12th Nov 20078:00 amRNSCancellation - 12/11/2007
7th Nov 20077:57 amRNSPublication of Prospectus
6th Nov 200712:51 pmRNSHolding(s) in Company
6th Nov 20077:00 amRNSDisposal
1st Nov 20075:53 pmRNSDirector/PDMR Shareholding
1st Nov 20077:02 amRNSPlacing
31st Oct 20079:20 amRNSTotal Voting Rights
18th Oct 20072:30 pmRNSDirector/PDMR Shareholding
12th Oct 20077:01 amRNSMove to the Official List
4th Oct 20077:01 amRNSDisposal of SyAqua Mexico
28th Sep 20077:01 amRNSTotal Voting Rights
24th Sep 20072:11 pmRNSDirector/PDMR Shareholding
18th Sep 20077:02 amRNSPreliminary Results
12th Sep 20072:55 pmRNSStatement re: Foot & Mouth
5th Sep 20075:16 pmRNSBlocklisting Interim Review
17th Aug 20072:55 pmRNSChange of Adviser
10th Aug 20074:28 pmRNSAIM Rule 26
6th Aug 20077:01 amRNSStatement Re: Foot & Mouth
25th Jul 20072:00 pmRNSBlocklisting Interim Review
18th Jul 20077:01 amRNSPre-Close Trading Update
7th Jun 20076:35 pmRNSHolding(s) in Company
7th Jun 20076:33 pmRNSHolding(s) in Company
19th Apr 20075:13 pmRNSDirector/PDMR Shareholding
12th Apr 200710:58 amRNSHolding(s) in Company
29th Mar 20077:00 amRNSHolding(s) in Company
13th Mar 20077:02 amRNSBoard Change
13th Mar 20077:01 amRNSInterim Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.